Calliditas Therapeutics AB has a consensus price target of $49.25, established from looking at the 9 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on February 22, 2024, November 27, 2023, and October 16, 2023. With an average price target of $50 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 165.96% upside for Calliditas Therapeutics AB from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/22/2024 | CALT | Buy Now | Calliditas Therapeutics | $18.80 | 165.96% | HC Wainwright & Co. | Arthur He | → $50 | Reiterates | Buy → Buy | Get Alert |
11/27/2023 | CALT | Buy Now | Calliditas Therapeutics | $18.80 | 165.96% | HC Wainwright & Co. | Arthur He | → $50 | Reiterates | Buy → Buy | Get Alert |
10/16/2023 | CALT | Buy Now | Calliditas Therapeutics | $18.80 | 165.96% | HC Wainwright & Co. | Edwin Zhang | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
08/21/2023 | CALT | Buy Now | Calliditas Therapeutics | $18.80 | 165.96% | HC Wainwright & Co. | Edwin Zhang | → $50 | Reiterates | Buy → Buy | Get Alert |
08/18/2023 | CALT | Buy Now | Calliditas Therapeutics | $18.80 | -4.26% | Guggenheim | Vamil Divan | $21 → $18 | Maintains | Neutral | Get Alert |
06/20/2023 | CALT | Buy Now | Calliditas Therapeutics | $18.80 | 219.15% | HC Wainwright & Co. | Edwin Zhang | → $60 | Initiates | → Buy | Get Alert |
03/01/2023 | CALT | Buy Now | Calliditas Therapeutics | $18.80 | -4.26% | Guggenheim | Vamil Divan | → $18 | Initiates | → Neutral | Get Alert |
02/24/2023 | CALT | Buy Now | Calliditas Therapeutics | $18.80 | 320.21% | Citigroup | Yigal Nochomovitz | $76 → $79 | Maintains | Buy | Get Alert |
12/20/2021 | CALT | Buy Now | Calliditas Therapeutics | $18.80 | 229.79% | HC Wainwright & Co. | Edwin Zhang | — | Maintains | Buy | Get Alert |
The latest price target for Calliditas Therapeutics (NASDAQ: CALT) was reported by HC Wainwright & Co. on February 22, 2024. The analyst firm set a price target for $50.00 expecting CALT to rise to within 12 months (a possible 171.30% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Calliditas Therapeutics (NASDAQ: CALT) was provided by HC Wainwright & Co., and Calliditas Therapeutics reiterated their buy rating.
There is no last upgrade for Calliditas Therapeutics.
There is no last downgrade for Calliditas Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Calliditas Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Calliditas Therapeutics was filed on February 22, 2024 so you should expect the next rating to be made available sometime around February 22, 2025.
While ratings are subjective and will change, the latest Calliditas Therapeutics (CALT) rating was a reiterated with a price target of $0.00 to $50.00. The current price Calliditas Therapeutics (CALT) is trading at is $18.43, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.